Castle Biosciences Inc (CSTL)
Castle Biosciences - New Analysis of 13,560 Patients DemonstratesDecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle Biosciences - New Analysis of 13,560 Patients DemonstratesDecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
There are no comments here yet...